参考文献/References:
[1] Chew BH, Lange D. Ureteral stent symptoms and associated infections: a biomaterials perspective[J]. Nat Rev Urol, 2009, 6(8): 440-448.
[2] Chew BH, Knudsen BH, Denstedt D. The use of stents in contemporary urology[J]. Curr Opin Urol, 2004, 14(2): 111-115.
[3] Miyaoka R, Monga M. Ureteral stent discomfort: Etiology and management[J]. Indian J Urol, 2009, 25(4): 455-460.
[4] Byrne RR, Auge BK, Kourambas J, et al. Routine ureteral stenting is not necessary after ureteroscopy and ureteropyeloscopy: a randomized trial[J]. J Endourol, 2002, 16(1): 9-13.
[5] Joshi HB, Okeke A, Newns N, et al. Characterization of urinary symptoms in patients with ureteral stents[J]. Urology, 2002, 59(4): 511-519.
[6] Beddingfield R, Pedro RN, Hinck B, et al. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study[J]. J Urol, 2009, 18(1): 170-176.
[7] Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study[J]. Urol Res, 2009, 37(3): 147-152.
[8] Agarwal A, Dhiraaj S, Singhal V, et al. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study[J]. Br J Anaesth, 2006, 96(3): 377-380.
[9] Lim KT, Kim YT, Lee TY, et al. Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts[J]. Korean J Urol, 2011, 52(7): 485-488.
[10] Yamada S, Ito Y, Tsukada H. α1 -Adrenoceptors and muscarinicic receptors in voiding function-binding characteristics of therapeutic agents in relation to the pharmacokinetics[J]. Br J Clin Pharmacol, 2011, 72(2): 205-217.